Georgia State University was highlighted in a press briefing Oct. 6 by the White House COVID-19 response team, which recognized the university’s contribution to groundbreaking research that led to the development of molnupiravir.
A new antiviral drug tested in the Institute for Biomedical Sciences at Georgia State against influenza virus and SARS-CoV-2 has been recommended for emergency use authorization to treat COVID-19 in the United States by pharmaceutical companies that completed a Phase 3 clinical trial and achieved promising results.
Few previous studies have examined functional abnormalities in the brain, which might reveal the physiological processes that underlie prolonged mental health symptoms in COVID-19 survivors.
The study found that the pandemic resulted in a six-to-eightfold increase in rates of intimate partner aggression across the U.S.
Professor Christopher Basler has received two grants from the National Institutes of Health to study two coronaviruses that cause human disease: Middle East respiratory syndrome (MERS) coronavirus and SARS-CoV-2.
Onika Anglin (B.A. '12) draws from her background as an anthropology and philosophy major in her public health work.
An analysis conducted by the Metro-Atlanta Policy Lab for Education has found substantial impacts on student achievement during the COVID-19 pandemic.
COVID-19 patients who receive oxygen therapy or experience fever show reduced gray matter volume in the frontal-temporal network of the brain.
Amid soaring gun sales and the pandemic, researchers at Georgia State are uncovering new solutions to protect young people from accidental shootings and suicides.
Viruses have an amazing capacity to mutate. But what if we could turn that against them? Richard Plemper, professor in the Institute for Biomedical Sciences, is working to exploit this rapid evolution.
